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Despite many perceived advances in treatment over the past few decades, cancer 
continues to present a significant health burden, particularly to the aging US population. 
Forces including shrinking funding mechanisms, cost and quality concerns, as well as 
disappointing clinical outcomes have driven a surge of recent efforts into utilizing the 
technological innovation that has permeated other industries by leveraging large and 
complex data sets, so called “big data.” In this review, we will review some of the history 
of oncology data collection, including the earliest data registries, as well as explore 
the future directions of this new brand of research while highlighting some of the more 
recent and promising efforts to harness the power of the electronic health record and the 
multitude of data co-located there, in an effort to improve individualized cancer-related 
outcomes in rapid real time.
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Both the Institute of Medicine and the American Society of Clinical Oncology (ASCO) have called 
for a “national quality reporting program for cancer care as part of a learning health care system” (1). 
Furthermore, the current Presidential administration has made cancer one of its priorities, announc-
ing its intentions to allocate additional funds for a “moonshot” to a cure. Cancer is a major public 
health issue, as it is the second leading cause of death in the US and is projected to surpass/exceed 
heart disease in the upcoming years. The lifetime risk of developing some form of cancer for men 
is 42% (1 in 2) and for women 38% (1 in 3). By 2030, the incidence of cancer will rise to 2.3 million 
cases per year as a result of the aging US population (2).
Recent cancer research budgets have been declining; however, the current climate is much 
more favorable. We find ourselves at crossroads of information technology, increased funding, and 
increased pressure for both quality care and cures.
In pursuit of these goals, and with the atmosphere of information technology, “big data” is an 
unchartered area in cancer. “Big data” is the term used for data sets that are so large or complex that 
traditional data sets processing applications are inadequate. The formation and management of these 
datasets can be exploited for real-time answers both in the efficacy of treatments in the real world 
as well as quality of care. As payers for health care in the United States and worldwide grapple with 
the movement away from fee for service-based reimbursement and toward payments for quality, 
information gleaned from large dataset may provide feedback that is crucial for improvements in 
the system. Additionally, “big data” compiled for research purposes provides a real-world laboratory 
for innovative treatments and interventions that may, in some places, fill in gaps where randomized 
prospective trials are impractical or cost prohibitive.
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Population-based, cancer incidence data in the United States 
have been collected by the National Cancer Institute’s (NCI’s) 
Surveillance, Epidemiology, and End Results (SEER) Program 
since 1973 and by the Centers for Disease Control and Prevention’s 
National Program of Cancer Registries (NPCR) since 1995 (2). 
The North American Association of Central Cancer Registries 
compiles and reports incidence data from 1995 onward for cancer 
registries that participate in the SEER program and/or the NPCR. 
These data approach 100% coverage of the US population in the 
most recent time period and were the source for the projected 
new cancer cases in 2016 (2). These databases have provided an 
invaluable resource in tracking, categorizing, and noting trends 
of cancer as a public health issue. However, these existing systems 
fail to track the quality of the care for cancer patients.
We are currently in the midst of an explosion of the informa-
tion industry. However, the information technology revolution 
has yet to mature in the medical field, despite near-universal 
penetrance of the electronic medical record. Many cancer 
patients experience highly fragmented care, with a combination 
of their records on paper, different electronic health record 
(EHR) systems, and physical disks for imaging, each housed 
in multiple locations. These uncoordinated and unconnected 
pieces of information impair the ability of oncologists to make 
an impact on the population scan and more difficult for the 
individual patient. Research based on an EHR is limited by 
the complexity of data collected and the context under which 
the data were collected. However, the EHR has unlocked the 
potential to turn individual level data into datasets that can 
provide information about the population and the efficacy of 
our interventions.
To repurpose the individual electronic pieces of a patient’s 
electronic chart into “big data,” data models must be created 
using clinical, administrative, and claims data. One such data-
set is the HMO Research Network Virtual Data Warehouse 
(VDW)—a public, non-proprietary, research-focused data model 
that currently consists of 17 sites that together cover 13 million 
individuals; in total, the VDW has over 185 million person-years 
of data (3). Using this VDW, Kaiser Permanente has developed 
clinical research networks that include a colorectal cancer cohort, 
a severe congenital heart disease cohort and an obesity cohort 
(4). It is important to establish that “big data” is different than 
conventional large databases, one is a system that purely collects 
data, whereas “big data” is harvesting the data and analyzing in a 
fashion that gives us real-time feedback that could help providers 
make decisions in patient care. This could be a turning point in 
our care of oncology patients if this were to be successful. The goal 
of “big data” is the capability to extract value from large amounts 
of data, not just collect it.
Over the past two decades, additional organizations have 
attempted to fill that quality void and establish guidelines 
for evidence-based cancer care. For example, the National 
Comprehensive Cancer Network was started in 1995 to establish 
practice guidelines for clinicians taking care of cancer patients. 
This has become an invaluable resource for clinicians. In addi-
tion, the American College of Surgeons and the American Cancer 
Society jointly sponsor the National Cancer Database (NCDB), 
which is a database that covers approximately 1,500 facilities and 
approximately 70% of new cancer diagnosis in the US. They have 
over 30 million records to date (5). In addition to the NCDB, the 
Commission on Cancer, which is part of the American College 
of Surgeons, started to use the NCDB data to establish whether 
institutions were meeting certain quality measures. This started 
with a few disease sites and now covers nine, with continued plans 
to broaden.
Once established, registries such as those as listed above 
provide insight to the epidemiology of cancer, but now with 
improved informational technology, we have the potential to 
harvest more complex and important data points. We are start-
ing to establish quality measures and analyze them compared 
to recognized national benchmarks that were not available or 
present before. Rapid advances in health information technol-
ogy have created unprecedented opportunities to learn from 
real-world data.
Many cancer organizations are making this a priority, includ-
ing ASCO, which has included “Big Data” as one of three major 
visions for cancer care (6). ASCO’s CancerLinQ initiative, aims to 
collate data from every cancer patient in the US and make it avail-
able for analysis in the hope that it will lead to new insights. Their 
goals not only want to impact on a population basis but for the 
individual patient and provider. They propose real-time feedback 
to the oncologist to help them choose certain therapies and make 
clinical decisions. They are using a global software company, to 
create a big data platform. Many such software vendors are now 
commercially available. In the private sector, Flatiron Health has 
created the OncologyCloud–a big data program that aims to 
collect data from the medical records, doctors’ notes, and bill-
ing information, to give real-time feedback to providers about 
treatments and outcomes. For example, part of their analytics can 
analyze cost of individual patient care, identify potential clinical 
trial candidates, which all streamlines with their specific EMR. 
Another example of “big data” harvesting is the Genomic Data 
Commons, this was developed and is housed at the University of 
Chicago, and here, they are using a “big data” approach to analyze 
cancer genomics. They are creating a cancer research community 
through a unified data repository promoting precision medicine, 
which is sponsored by the NCI.
We are in a transition time, as technology continues to expo-
nentially improve, soon we will be able to extract all the data and 
quality measures that we need directly from the EHR. The goal 
of big data would be to not only link current registry databases 
but gather all data on all cancer patients and then use to analyze 
outcomes, which has never been done before. But ultimately the 
goal of “big data” is bigger and aspirational, it not only improved 
quality of care but also actual answers to cancer, and improved 
outcomes. For example, many of the chemotherapy regimens we 
use today have been adopted because they demonstrated a benefit 
of survival in a clinical trial. Over decades, pharmaceutical tri-
als and cooperative groups have labored through the model of 
expensive, lengthy trials to get answers on which chemotherapy 
to use in which setting. This has been the standard of how we 
prove drug A is better than drug B. However, this paradigm 
represents only a small fraction of the total number of patients 
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with cancer (<5%). The advent of precision medicine has subdi-
vided even common malignancies into increasing small subtypes 
making large prospective trials increasingly burdensome. “Big 
data” offers the potential to harness all of the data from all of our 
cancer patients. We could collect, harness, and analyze patients’ 
clinical information and link it to molecular data and treatment 
outcomes to find answers to many of cancer’s most elusive ques-
tions in real time.
The importance of health information technology in our 
pursuit of quality and cure cannot be underestimated. New, 
innovative, and affordable approaches to quality assessment and 
improvement as well as treatment efficacy will depend on our 
ability to create and maintain “big data.”
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